Form 4: AnaptysBio Director John P. Schmid Converts Restricted Stock Units into Common Stock

AnaptysBio, Inc. Director John P. Schmid has converted 6,030 Restricted Stock Units (RSUs) into common stock, increasing his direct beneficial ownership.

Summary

• John P. Schmid, a Director of AnaptysBio, Inc. (ANAB), reported a transaction on June 15, 2025.
• The transaction involved the acquisition of 6,030 shares of Common Stock through the conversion of Restricted Stock Units (RSUs) at a price of $0 per share.
• Following this transaction, Mr. Schmid directly beneficially owns 52,267 shares of Common Stock.
• Additionally, 11,068 shares of Common Stock are indirectly beneficially owned by an ESOP, for which Mr. Schmid is a trustee, though he disclaims beneficial ownership beyond his less than 1% pecuniary interest.
• The RSUs vested 100% on the date of the Issuer's 2025 annual meeting of shareholders, contingent on Mr. Schmid's continued service.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as the transaction represents a director increasing their direct stake in the company through the vesting of equity compensation, which generally aligns insider interests with shareholders. There are no negative aspects reported.

Positives

• The conversion of Restricted Stock Units into common stock indicates the vesting and settlement of equity compensation for a director, aligning his interests with shareholders.
• The increase in direct beneficial ownership by a director can be viewed as a positive signal of confidence in the company's future.

Negatives

• No direct negative implications are apparent from this routine insider transaction filing.

Risks

• No specific risks are detailed within this Form 4 filing, as it primarily reports an insider transaction.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction. It solely reports an insider equity transaction.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity transaction and does not provide broader industry context or trends. It reflects a standard compensation event for a director within the biotechnology sector.

Stakeholder Impact

• Shareholders: The increase in direct beneficial ownership by a director may be viewed positively as it aligns management's interests with shareholder value.
• Employees: The transaction is related to equity compensation, a common practice to incentivize and retain key personnel.

Next Steps

• The RSUs vested on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's continued provision of service.

Key Dates

Recommendation

Keywords

AnaptysBio, ANAB, John P. Schmid, Form 4, SEC filing, insider transaction, restricted stock units, RSU conversion, common stock, beneficial ownership, director